H
Howard T. Thaler
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 198
Citations - 22557
Howard T. Thaler is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Survival rate. The author has an hindex of 79, co-authored 198 publications receiving 21473 citations. Previous affiliations of Howard T. Thaler include NewYork–Presbyterian Hospital & Keio University.
Papers
More filters
Journal ArticleDOI
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress
Russell K. Portenoy,Howard T. Thaler,Alice B. Kornblith,J. McCarthy Lepore,Hamutal Friedlander-Klar,E. Kiyasu,K. Sobel,N. Coyle,Nancy E. Kemeny,Larry Norton,Howard I. Scher +10 more
TL;DR: High correlations with clinical status and quality of life measures support the validity of the MSAS and indicate the utility of several subscale scores, including PSYCH, PHYS, and a brief Global Distress Index.
Journal Article
Total mesorectal excision in the operative treatment of carcinoma of the rectum
TL;DR: Total mesorectal excision cures carcinoma of the rectum and provides excellent local control through resection of the entire unit of regional spread that is excised, intact and with negative circumferential margins.
Journal ArticleDOI
Distribution of Brain Metastases
TL;DR: The data suggest that the high incidence of subtentorial lesions in patients with pelvic and gastrointestinal primary tumors cannot be explained by arterial embolization alone, and that this peculiar distribution is probably not explained by seeding of the brain through Batson's plexus.
Journal Article
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Lisa M. Butler,David B. Agus,Howard I. Scher,Brian Higgins,Adam Rose,Carlos Cordon-Cardo,Howard T. Thaler,Richard A. Rifkind,Paul A. Marks,Victoria M. Richon +9 more
TL;DR: The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.
Journal ArticleDOI
Symptom prevalence, characteristics and distress in a cancer population
Russell K. Portenoy,Howard T. Thaler,Alice B. Kornblith,J. McCarthy Lepore,Hamutal Friedlander-Klar,N. Coyle,T. Smart-Curley,Nancy E. Kemeny,Larry Norton,William J. Hoskins,Howard I. Scher +10 more
TL;DR: In this article, a validation study of a new symptom assessment instrument, inpatients and outpatients with prostate, colon, breast or ovarian cancer were evaluated using the Memorial Symptom Assessment Scale and other measures of psychological condition, performance status, symptom distress and overall quality of life.